Cargando…

Efficacy and effect of free treatment on multidrug-resistant tuberculosis

Multidrug-resistant tuberculosis (MDR-TB) is a serious public health and social issue. It pertains to the type of tuberculosis that is resistant simultaneously to isoniazid and rifampicin. MDR-TB has a high mortality and is expensive to treat. The aim of the present study was to examine the therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales:	ZHANG, QING, WU, ZHEYUAN, ZHANG, ZURONG, SHA, WEI, SHEN, XIN, XIAO, HEPING
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774331/ https://www.ncbi.nlm.nih.gov/pubmed/26997992 http://dx.doi.org/10.3892/etm.2015.2966

Ejemplares similares

Effect of the Xpert MTB/RIF on the detection of pulmonary tuberculosis cases and rifampicin resistance in Shanghai, China
por: Wu, Zheyuan, et al.
Publicado: (2020)

A highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis: a multicenter prospective study in China
por: Sun, Wenwen, et al.
Publicado: (2021)

Effect of mobile health reminders on tuberculosis treatment outcomes in Shanghai, China: A prospective cohort study
por: Wu, Zheyuan, et al.
Publicado: (2023)

Resistance to Second-Line Antituberculosis Drugs and Delay in Drug Susceptibility Testing among Multidrug-Resistant Tuberculosis Patients in Shanghai
por: Chen, Yong, et al.
Publicado: (2016)

82125 Multiple epidemics of multidrug-resistant tuberculosis revealed by spatial disease mapping and whole-genome sequencing analysis in urban China
por: Yang, Chongguang, et al.
Publicado: (2021)

Prediction of drug resistance profile of multidrug-resistant Mycobacterium tuberculosis (MDR-MTB) isolates from newly diagnosed case by whole genome sequencing (WGS): a study from a high tuberculosis burden country
por: Sun, Wenwen, et al.
Publicado: (2022)

Treatment outcomes of patients with multidrug and extensively drug-resistant tuberculosis in Zhejiang, China
por: Zhang, Ming-Wu, et al.
Publicado: (2021)

Diagnosis and treatment of multidrug-resistant tuberculosis
por: Jang, Jong Geol, et al.
Publicado: (2020)

Treatment outcomes for multidrug-resistant tuberculosis in Eastern Taiwan
por: Lin, Chih-Bin, et al.
Publicado: (2019)

Extensively Drug-Resistant Tuberculosis, China
por: Tang, Shenjie, et al.
Publicado: (2011)

Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant Tuberculosis
por: Tang, Peijun, et al.
Publicado: (2022)

Use of Whole-Genome Sequencing to Predict Mycobacterium tuberculosis Complex Drug Resistance from Early Positive Liquid Cultures
por: Wu, Xiaocui, et al.
Publicado: (2022)

Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosis
por: Tupasi, Thelma, et al.
Publicado: (2016)

Multidrug-resistant tuberculosis
por: Zager, Ellen M, et al.
Publicado: (2008)

Multidrug-resistant tuberculosis
por: Lemos, Antônio Carlos Moreira, et al.
Publicado: (2013)

Multidrug-Resistant Tuberculosis in Patients with Chronic Obstructive Pulmonary Disease in China
por: Zhao, Jiang-nan, et al.
Publicado: (2015)

Predictors of Treatment Success for Multidrug Resistant Tuberculosis
por: Park, Sang Won
Publicado: (2016)

Medical Treatment of Pulmonary Multidrug-Resistant Tuberculosis
por: Shim, Tae Sun, et al.
Publicado: (2013)

Profile of delamanid for the treatment of multidrug-resistant tuberculosis
por: Szumowski, John D, et al.
Publicado: (2015)

Treatment Outcomes Associated with Multidrug-resistant Tuberculosis
por: Gupta, Nitin, et al.
Publicado: (2018)

Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging
por: Li, Yang, et al.
Publicado: (2018)

The Relationship between Extensively Drug-Resistant Tuberculosis and Multidrug-Resistant Gram-Negative Bacilli
por: Zhao, Jiang-nan, et al.
Publicado: (2015)

Promising of Multidrug-resistant Tuberculosis Screening among New Tuberculosis Patients in China
por: Zhang, Hui, et al.
Publicado: (2017)

Pharmacotherapy for multidrug resistant tuberculosis
por: Chhabra, Naveen, et al.
Publicado: (2012)

The Threat of Multidrug-resistant Tuberculosis
por: Paul, Rudrajit
Publicado: (2018)

Fistulized multidrug-resistant tuberculosis
por: El Omri, Naoual, et al.
Publicado: (2017)

Model-Based Efficacy and Toxicity Comparisons of Moxifloxacin for Multidrug-Resistant Tuberculosis
por: Yun, Hwi-Yeol, et al.
Publicado: (2021)

Sequelae of pulmonary multidrug-resistant tuberculosis at the completion of treatment
por: Singla, Rupak, et al.
Publicado: (2018)

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
por: Mbuagbaw, Lawrence, et al.
Publicado: (2019)

New Leads for the Treatment of Multidrug Resistant Mycobacterium tuberculosis
por: Herzon, Seth B.
Publicado: (2020)

Treatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel
por: Lange, Christoph, et al.
Publicado: (2022)

Risk factors for the occurrence of multidrug-resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis treatment in East Shoa, Ethiopia
por: Desissa, Fanta, et al.
Publicado: (2018)

Cycloserine for treatment of multidrug-resistant tuberculosis: a retrospective cohort study in China
por: Li, Yang, et al.
Publicado: (2019)

Significance of the Differential Peptidome in Multidrug-Resistant Tuberculosis
por: Yang, Yan, et al.
Publicado: (2019)

Adjunctive Zoledronate + IL-2 administrations enhance anti-tuberculosis Vγ2Vδ2 T-effector populations, and improve treatment outcome of multidrug-resistant tuberculosis(1)
por: Shen, Hongbo, et al.
Publicado: (2022)

Multidrug-resistant tuberculosis/rifampicin-resistant tuberculosis: Principles of management
por: Prasad, Rajendra, et al.
Publicado: (2018)

Treatment outcomes of multidrug-resistant tuberculosis in Hangzhou, China, 2011 to 2015
por: Li, Qingchun, et al.
Publicado: (2020)

Multidrug-resistant Tuberculosis Lymphadenitis as the Initial Presentation of Secondary Multidrug-resistant Tuberculosis: A Case Report
por: Ogundipe, Temitayo, et al.
Publicado: (2018)

Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB)
por: Sabur, Natasha F., et al.
Publicado: (2021)

Efficacy and safety of cycloserine-containing regimens in the treatment of multidrug-resistant tuberculosis: a nationwide retrospective cohort study in China
por: Wang, Jing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bc4csrgilf07t5bknlump3dfgu